How Much Do GLP-1 Medications Cost Without Insurance in 2026?

GLP-1 medications are among the most expensive prescription drugs in the United States. Without insurance, a monthly supply of semaglutide (Ozempic or Wegovy) or tirzepatide (Mounjaro or Zepbound) costs between $900 and $1,400 at retail pharmacy prices. For most patients, that is not a sustainable out-of-pocket expense — which is why understanding manufacturer savings programs, prior authorization pathways, and lower-cost alternatives is essential before starting treatment.

The short answer: Without insurance, GLP-1 drugs cost $900–$1,400/month at list price. With manufacturer savings cards, commercially insured patients often pay $25–$150/month. Medicare patients face the most significant barriers, as most GLP-1 drugs for obesity are not covered under Part D (with the exception of Wegovy for cardiovascular risk reduction in eligible patients).

2026 GLP-1 Drug Prices: At a Glance

*Savings card eligibility typically requires commercial insurance; Medicare/Medicaid patients are excluded.

Why GLP-1 Drugs Are So Expensive

GLP-1 receptor agonists are biologic-adjacent peptide drugs that require complex manufacturing processes. Unlike small-molecule drugs (such as metformin or lisinopril) that can be synthesized cheaply and generically, GLP-1 drugs are large peptide molecules that must be manufactured under tightly controlled biological conditions.

Additionally, Novo Nordisk (maker of Ozempic, Wegovy, Victoza, and Rybelsus) and Eli Lilly (maker of Mounjaro, Zepbound, and Trulicity) hold active patents on their GLP-1 formulations. No generic versions are available as of 2026, and the earliest patent expirations for semaglutide are not expected until the late 2020s. The FDA has also not yet approved any biosimilar GLP-1 drugs, though several are in development.

The result is a market where manufacturers set prices with limited competitive pressure, and pharmacy benefit managers negotiate rebates that reduce net prices for insurers but not for uninsured patients.

Manufacturer Savings Programs

Both Novo Nordisk and Eli Lilly offer savings programs that dramatically reduce out-of-pocket costs for commercially insured patients.

Novo Nordisk Savings Programs

Ozempic Savings Card: Eligible commercially insured patients can pay as little as $25 for a 1-month or 3-month supply. The program covers up to $150/month in savings. Patients must have commercial insurance (Medicare, Medicaid, and other government programs are excluded). Enrollment is available at ozempic.com/savings.

Wegovy Savings Card: Similar structure — as low as $25/month for eligible commercially insured patients. Enrollment at wegovy.com/savings.

Rybelsus Savings Card: As low as $10 for a 30-day supply for eligible patients. Enrollment at rybelsus.com.

Eli Lilly Savings Programs

Mounjaro Savings Card: Eligible commercially insured patients can pay as little as $25/month. Enrollment at mounjaro.com.

Zepbound Savings Card: As low as $25/month for eligible commercially insured patients. Enrollment at zepbound.com.

Lilly Cares Foundation: For uninsured or underinsured patients who do not qualify for the savings card, Lilly's patient assistance program may provide medication at no cost. Income eligibility requirements apply.

Important Limitations

Savings cards are not available to patients with Medicare Part D, Medicaid, TRICARE, or other federal healthcare programs. This is a legal restriction under the federal anti-kickback statute, which prohibits manufacturers from subsidizing costs for government program beneficiaries. For Medicare patients, the primary savings pathway is the Medicare Part D Extra Help program (Low Income Subsidy), which can significantly reduce cost-sharing for covered medications.

Medicare Coverage: The Most Complex Situation

Medicare Part D has historically been prohibited from covering weight loss medications under the Social Security Act. This exclusion applied to Wegovy, Saxenda, and other obesity drugs regardless of clinical evidence.

The landscape changed partially in 2024 when the FDA approved Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight. CMS subsequently determined that Wegovy qualifies for Part D coverage under the cardiovascular indication — but only for patients who meet the specific criteria (established CVD plus BMI ≥27). Medicare patients with obesity alone, without cardiovascular disease, remain without coverage.

For Medicare patients with type 2 diabetes, Ozempic, Mounjaro, Victoza, and Trulicity are generally covered under Part D for the diabetes indication, subject to formulary placement and cost-sharing.

Medicare Part D Cost-Sharing (Typical)

Under the redesigned Part D benefit (effective 2025), the maximum out-of-pocket cap for covered drugs is $2,000/year. For a drug like Ozempic at ~$935/month list price, a patient in the coverage gap would pay approximately 25% coinsurance until reaching the $2,000 cap, after which coverage is catastrophic.

Compounded Semaglutide: The Controversial Lower-Cost Option

During the semaglutide shortage period (2022–2024), the FDA allowed compounding pharmacies to produce compounded semaglutide, which could be sold at significantly lower prices ($200–$400/month). This created a large market for compounded GLP-1 drugs.

As of 2025, the FDA declared the semaglutide shortage resolved and issued guidance that compounding pharmacies should no longer produce copies of Ozempic or Wegovy. However, enforcement has been inconsistent, and compounded semaglutide remains available from some telehealth platforms and compounding pharmacies.

Key risks of compounded semaglutide:

• Not FDA-approved; no guarantee of potency, purity, or sterility
• Some products have used semaglutide sodium salt (not the same as semaglutide free base used in FDA-approved products) — the FDA has warned this may not be bioequivalent
• No manufacturer pharmacovigilance or adverse event reporting
• Telehealth platforms offering compounded GLP-1s vary widely in clinical oversight quality

Patients considering compounded semaglutide should weigh the cost savings against these risks and discuss with their prescribing physician.

Telehealth Platforms and Their Pricing

Several telehealth platforms have built businesses around GLP-1 prescriptions, often bundling the prescription with coaching, monitoring, and compounded or branded medications. Pricing varies significantly:

Platforms offering branded medications typically require commercial insurance and use the manufacturer savings cards. Platforms offering compounded medications provide a lower-cost option but with the risks described above.

Patient Assistance Programs

For uninsured patients who do not qualify for savings cards and cannot afford list prices, manufacturer patient assistance programs (PAPs) provide free or heavily discounted medication:

Novo Nordisk Patient Assistance Program (NovoCare): Provides free Ozempic, Wegovy, and Rybelsus to eligible uninsured or underinsured patients. Income eligibility is typically ≤400% of the federal poverty level. Apply at novonordisk-us.com/patients/patient-assistance-program.html.

Lilly Cares Foundation: Provides free Mounjaro and Zepbound to eligible patients. Income and insurance eligibility requirements apply. Apply at lillycares.com.

NeedyMeds.org and RxAssist.org maintain databases of all manufacturer PAPs and can help patients identify eligibility.

The Bottom Line

Without insurance, GLP-1 medications cost $900–$1,400/month — prices that are out of reach for most patients. The most effective cost-reduction strategies, in order of impact:

1. Get insurance coverage — work with your prescriber to document the appropriate diagnosis (type 2 diabetes, obesity with comorbidities, or cardiovascular disease) and pursue prior authorization
2. Use manufacturer savings cards — commercially insured patients can reduce costs to $25/month
3. Apply for patient assistance — uninsured patients below income thresholds can receive medication free through NovoCare or Lilly Cares
4. Consider telehealth platforms — some offer streamlined prior authorization support and savings card enrollment
5. Discuss alternatives — older GLP-1 drugs like liraglutide (Victoza) and dulaglutide (Trulicity) are less expensive and may be appropriate for some patients

For current pricing at pharmacies near you, see the semaglutide cost page and tirzepatide cost page on RxGuide.

Sources

1. GoodRx. GLP-1 Drug Prices and Coupons. 2026. https://www.goodrx.com
2. Novo Nordisk. Ozempic Savings Card Terms and Conditions. 2026. https://www.ozempic.com/savings
3. Eli Lilly. Mounjaro Savings Card. 2026. https://www.mounjaro.com/savings
4. Centers for Medicare & Medicaid Services. Medicare Part D Coverage of Anti-Obesity Medications. 2024. https://www.cms.gov
5. FDA. Compounded Drug Products Containing Semaglutide. 2025. https://www.fda.gov/drugs/human-drug-compounding/compounded-drug-products-containing-semaglutide
6. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002.